T. Rowe Price Associates
TSVT

T. Rowe Price Associates’s 2seventy bio TSVT Stock Holding History

T. Rowe Price Associates’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,033
Closed -$109K – 3150
2025
Q1 		$109K Buy
22,033
+3,808
+21% +$12.1K ﹤0.01% 2803
2024
Q4 		$54K Sell
18,225
-10,987
-38% -$45.1K ﹤0.01% 2933
2024
Q3 		$138K Buy
29,212
+283
+1% +$1.28K ﹤0.01% 2765
2024
Q2 		$112K Hold
28,929
– – ﹤0.01% 2737
2024
Q1 		$155K Buy
28,929
+2,893
+11% +$13.6K ﹤0.01% 2691
2023
Q4 		$112K Buy
26,036
+1,482
+6% +$4.55K ﹤0.01% 2696
2023
Q3 		$97K Buy
24,554
+4,626
+23% +$30.3K ﹤0.01% 2678
2023
Q2 		$202K Sell
19,928
-586,826
-97% -$6.21M ﹤0.01% 2527
2023
Q1 		$6.19M Buy
606,754
+590,613
+3,659% +$6.75M ﹤0.01% 1137
2022
Q4 		$151K Buy
16,141
+596
+4% +$8.41K ﹤0.01% 2617
2022
Q3 		$227K Buy
+15,545
New +$231K ﹤0.01% 2495

Other funds holding TSVT

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T. Rowe Price Associates's TSVT Position: Q2 2025 in Review

T. Rowe Price Associates sold out of 2seventy bio (TSVT) in Q2 2025, closing a stake of 22,033 shares — an estimated $109K sold.

T. Rowe Price Associates first reported a position in TSVT in Q3 2022 and held it in 11 quarters. The position peaked at $6.19M in Q1 2023. 2 funds tracked by Wall St. Rank hold TSVT as of Q2 2025.

  • T. Rowe Price Associates reported no remaining 2seventy bio position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 22,033 2seventy bio shares in Q2 2025, an estimated $109K.
  • T. Rowe Price Associates first reported a position in 2seventy bio in Q3 2022 and held it in 11 quarters.
  • T. Rowe Price Associates's 2seventy bio position peaked at $6.19M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.